Curt D. Furberg

Q: What Schools Are Affiliated With Curt D. Furberg

Curt D. Furberg is affiliated with the following schools: Wake Forest University, Royal Postgraduate Medical School, United States Military Academy, Johns Hopkins University, University of Washington

Curt D. Furberg's AcademicInfluence.com Rankings

Curt D. Furberg

Philosophy

#3098

World Rank

#5084

Historical Rank

Logic

#949

World Rank

#1546

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Curt D. Furberg's Degrees

Doctorate Medicine University of Basel

Why Is Curt D. Furberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Curt D. Furberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. (1998) (6291)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2002) (5253)
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
The Cardiovascular Health Study: design and rationale. (1991) (3623)
Fundamentals of Clinical Trials (1982) (1595)
Incidence of and risk factors for atrial fibrillation in older adults. (1997) (1461)
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. (2000) (1287)
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). (2002) (1272)
Assessment of quality of life in clinical trials of cardiovascular therapies. (1984) (1207)
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. (1995) (1174)
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). (1994) (1146)
Genome-wide meta-analyses identify multiple loci associated with smoking behavior (2010) (1107)
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. (2003) (1073)
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. (2001) (992)
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. (1994) (892)
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. (2007) (837)
Lipoprotein Management in Patients With Cardiometabolic Risk (2008) (796)
A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers (2009) (767)
Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency (2003) (763)
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. (2007) (760)
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. (2009) (751)
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. (1997) (723)
Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study (2000) (696)
Ginkgo biloba for prevention of dementia: a randomized controlled trial. (2008) (593)
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. (2008) (581)
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use (2010) (577)
Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (1996) (573)
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. (1985) (564)
Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. (1993) (561)
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. (2008) (554)
Depressive Symptoms and Risks of Coronary Heart Disease and Mortality in Elderly Americans (2000) (529)
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) (1995) (516)
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. (2008) (509)
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). (2002) (507)
Cholesterol reduction yields clinical benefit: impact of statin trials. (1998) (506)
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk (2011) (504)
Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. (2008) (503)
Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events (2000) (497)
Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study (2002) (490)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis (2009) (485)
Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. (2007) (435)
Incidence, Manifestations, and Predictors of Worsening White Matter on Serial Cranial Magnetic Resonance Imaging in the Elderly: The Cardiovascular Health Study (2005) (429)
Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project (2000) (422)
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. (1989) (416)
Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. (2001) (399)
Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. (1996) (396)
Physical Activity and Incidence of Atrial Fibrillation in Older Adults: The Cardiovascular Health Study (2008) (385)
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease (2004) (377)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials (2000) (376)
The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. (1986) (356)
Withdrawal of cerivastatin from the world market (2001) (355)
Assessment and Control for Confounding by Indication in Observational Studies (1999) (335)
Secondary prevention after myocardial infarction: a review of long-term trials. (1982) (320)
Cholesterol reduction yields clinical benefit. A new look at old data. (1995) (297)
Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. (1994) (297)
Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. (1995) (296)
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis (2011) (295)
Incidence, Manifestations, and Predictors of Brain Infarcts Defined by Serial Cranial Magnetic Resonance Imaging in the Elderly: The Cardiovascular Health Study (2002) (289)
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk (2004) (277)
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. (1991) (271)
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. (2001) (270)
Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. (1992) (265)
COX-2 inhibitors--lessons in drug safety. (2005) (258)
Health Outcomes Associated with Antihypertensive Therapies Used as First-Line Agents: A Systematic Review and Meta-analysis (1998) (241)
Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old (1996) (237)
Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials (2011) (231)
Fundamentals of Clinical Trials. (2nd ed.). (1987) (231)
Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. (1987) (230)
Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. (1998) (229)
Reductase inhibitor monotherapy and stroke prevention. (1997) (228)
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use (2008) (223)
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). (2005) (218)
Reproducibility of Noninvasive Ultrasonic Measurement of Carotid Atherosclerosis: The Asymptomatic Carotid Artery Plaque Study (1992) (218)
Why guideline-making requires reform. (2009) (216)
Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. (2004) (216)
Associations of Postmenopausal Estrogen Use With Cardiovascular Disease and Its Risk Factors in Older Women (1993) (214)
The Association Between Lipid Levels and the Risks of Incident Myocardial Infarction, Stroke, and Total Mortality: The Cardiovascular Health Study (2004) (205)
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease (2005) (200)
Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria (1999) (198)
β-Adrenergic Blockade for Survivors of Acute Myocardial Infarction (1984) (195)
Effect of antiarrhythmic drugs on mortality after myocardial infarction. (1983) (195)
Thiazolidinediones and Heart Failure (2007) (195)
Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. (2001) (194)
Coronary Heart Disease in Patients With Low LDL-Cholesterol: Benefit of Pravastatin in Diabetics and Enhanced Role for HDL-Cholesterol and Triglycerides as Risk Factors (2002) (193)
Trends in pharmacologic management of hypertension in the United States. (1995) (188)
Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. (1985) (188)
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. (1999) (187)
Isolated systolic hypertension and subclinical cardiovascular disease in the elderly. Initial findings from the Cardiovascular Health Study. (1992) (187)
Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II) (2002) (184)
Statin use and breast cancer: prospective results from the Women's Health Initiative. (2006) (182)
Early age-related maculopathy in the cardiovascular health study. (2003) (179)
Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. (1999) (176)
Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. (1991) (173)
Cardiovascular disease risk status in elderly persons with renal insufficiency. (2002) (168)
Health outcomes associated with various antihypertensive therapies used as first-line agents (2003) (167)
Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. (2002) (165)
Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. (2000) (164)
Effect of pravastatin in people with diabetes and chronic kidney disease. (2005) (163)
From knowledge to practice in chronic cardiovascular disease: a long and winding road. (2004) (162)
Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. (1994) (155)
Effect of propranolol in postinfarction patients with mechanical or electrical complications. (1984) (155)
The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. (2006) (155)
Ensuring the integrity of clinical practice guidelines: a tool for protecting patients (2013) (153)
Differences in Medical Care and Disease Outcomes Among Black and White Women With Heart Disease (2003) (151)
Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review. (1988) (148)
The randomized clinical trial: bias in analysis. (1981) (148)
Suicidal Behavior and Depression in Smoking Cessation Treatments (2011) (145)
Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. (2000) (145)
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). (1995) (144)
Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. (1996) (141)
Natural statins and stroke risk. (1999) (139)
The record on rosiglitazone and the risk of myocardial infarction. (2007) (137)
Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis (2004) (137)
Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. (1989) (136)
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. (1996) (136)
I, RATIONALE AND DESIGN (1991) (136)
Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. (1986) (134)
Antihypertensive drugs decrease risk of Alzheimer disease (2013) (131)
Age as a modifiable risk factor for cardiovascular disease (2008) (131)
Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. (2002) (131)
Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2006) (125)
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. (1998) (124)
Use of calcium channel blockers and breast carcinoma risk in postmenopausal women (1997) (119)
Parecoxib, valdecoxib, and cardiovascular risk. (2005) (118)
Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. (1999) (117)
Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. (1986) (117)
Scientific Statement From the American Heart Association Use of Nonsteroidal Antiinflammatory Drugs : An Update for Clinicians: A (2007) (116)
Rosiglitazone and cardiovascular risk. (2007) (116)
Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). (2006) (115)
Estrogen Replacement Therapy and Progression of Intimal-Medial Thickness in the Carotid Arteries of Postmenopausal Women (1995) (113)
Are drugs within a class interchangeable? (1999) (113)
Effect of vasodilators on survival in chronic congestive heart failure. (1985) (111)
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. (1996) (107)
Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. (2000) (107)
Time to act on drug safety. (1998) (107)
A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization (2011) (107)
Controlled Clinical Trials of Drug Treatment for Hypertension A Review (1989) (106)
Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (2002) (106)
Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials (2014) (106)
Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C (2015) (105)
Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. (1999) (103)
Risk Factors and Secondary Prevention in Women with Heart Disease: The Heart and Estrogen/progestin Replacement Study (2003) (102)
Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. (1998) (100)
Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. (1996) (100)
Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. (1998) (99)
Venous thromboembolic events associated with hormone replacement therapy. (1997) (97)
Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods. (1986) (96)
Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications (2012) (96)
Usefulness of T-axis deviation as an independent risk indicator for incident cardiac events in older men and women free from coronary heart disease (the Cardiovascular Health Study). (2001) (96)
Risk Factors for Hospitalized Gastrointestinal Bleeding Among Older Persons (2001) (95)
Prescription Drugs Associated with Reports of Violence Towards Others (2010) (95)
Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy (2002) (94)
Long term propranolol treatment and changes in body weight after myocardial infarction. (1990) (93)
Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine. (1992) (91)
Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group. (1989) (90)
Association Between Blood Pressure Level and the Risk of Myocardial Infarction, Stroke, and Total Mortality (2001) (89)
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. (2002) (89)
Long-Term and Short-Term Changes in Antihypertensive Prescribing by Office-Based Physicians in the United States (2006) (88)
Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. (2001) (88)
Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: the Cardiovascular Health Study. (2007) (87)
Impact of Clinical Trial Results on National Trends in α-Blocker Prescribing, 1996-2002 (2004) (87)
Studies on an extra pre-beta lipoprotein fraction. (1972) (86)
Attempted control of hyperglycemia during cardiopulmonary bypass fails to improve neurologic or neurobehavioral outcomes in patients without diabetes mellitus undergoing coronary artery bypass grafting. (2005) (85)
Surgical bleeding: unexpected effect of a calcium antagonist (1995) (85)
Biologic determinants of propranolol disposition: Results from 1308 patients in the beta‐blocker heart attack trial * (1985) (83)
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? (2010) (83)
Subgroup Interactions in the Heart and Estrogen/Progestin Replacement Study: Lessons Learned (2002) (82)
Pravastatin, lipids, and major coronary events. (1994) (81)
The FDA and drug safety: a proposal for sweeping changes. (2006) (80)
Are all angiotensin-converting enzyme inhibitors interchangeable? (2001) (80)
Secondary prevention after myocardial infarction: a review of short-term acute phase trials. (1983) (80)
Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group. (1994) (79)
The necessity for clinical reasoning in the era of evidence-based medicine. (2013) (78)
Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. (1992) (78)
Antihypertensive drug therapies and the risk of ischemic stroke. (2001) (77)
Utility of new electrocardiographic models for left ventricular mass in older adults. The Cardiovascular Health Study Collaborative Research Group. (1996) (76)
Cost-minimization and the number needed to treat in uncomplicated hypertension. (1998) (75)
Treatment of hypertensive patients with diabetes (1998) (72)
Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. (2001) (72)
Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2012) (72)
Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience. (2006) (72)
Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. (2004) (70)
Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? (2006) (69)
Beyond hypertension toward guidelines for cardiovascular risk reduction. (2004) (67)
Characteristics and Baseline Clinical Predictors of Future Fatal Versus Nonfatal Coronary Heart Disease Events in Older Adults: The Cardiovascular Health Study (2006) (67)
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. (2004) (66)
Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). (1997) (65)
Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. (1995) (64)
Data Monitoring in Clinical Trials: A Case Studies Approach (2005) (64)
Adrenergic beta-blockade and electrocardiographical ST-T changes. (2009) (64)
Diabetes and Cognitive Decline in Older Adults: The Ginkgo Evaluation of Memory Study (2017) (60)
Comparison of mortality risk for electrocardiographic abnormalities in men and women with and without coronary heart disease (from the Cardiovascular Health Study). (2006) (60)
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events (1997) (59)
Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. (2004) (59)
Clinical value of intracoronary streptokinase. (1984) (59)
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. (2014) (59)
Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. (1995) (59)
Progression and regression of carotid atherosclerosis in clinical trials. (1991) (59)
Blood Pressure and Cardiovascular Disease (2010) (57)
Prevalence, Prognosis, and Implications of Isolated Minor Nonspecific ST-Segment and T-Wave Abnormalities in Older Adults: Cardiovascular Health Study (2008) (56)
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. (2007) (55)
Mortality in Pharmacologically Treated Older Adults with Diabetes: The Cardiovascular Health Study, 1989–2001 (2006) (55)
The effect of modified limb electrode positions on electrocardiographic wave amplitudes. (1980) (54)
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. (2010) (52)
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension (2001) (52)
Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2011) (52)
ALLHAT: Setting the Record Straight (2004) (52)
Calcium antagonists: not appropriate as first line antihypertensive agents. (1996) (51)
Lessons from overviews of cardiovascular trials. (1987) (51)
Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience. (1990) (51)
Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. (1995) (50)
Use of Herbal Medicine and Other Dietary Supplements in Community‐Dwelling Older People: Baseline Data from the Ginkgo Evaluation of Memory Study (2006) (50)
Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. (2011) (50)
Major clinical trials of hypertension: what should be done next? (2005) (50)
Effect of drug therapy on survival in chronic congestive heart failure. (1988) (49)
Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. (1999) (49)
Recent trials in hypertension: compelling science or commercial speech? (2006) (48)
The FDA and new safety warnings. (2012) (48)
Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. (2012) (47)
Methodological issues facing studies of atherosclerotic change. (1993) (46)
Isoprostane 8‐epi‐PGF2α is frequently increased in patients with muscle pain and/or CK‐elevation after HMG‐Co‐enzyme‐A‐reductase inhibitor therapy (2001) (46)
Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical trials and epidemiological studies. (1986) (45)
Hypertension guidelines: criteria that might make them more clinically useful. (2002) (44)
Correlates of QT prolongation in older adults (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. (1994) (44)
Treatment of Isolated Systolic Hypertension Is Most Effective in Older Patients With High-Risk Profile (2001) (44)
Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. (2010) (43)
Are we biased in our approach to treating elderly patients with heart disease? (1991) (43)
Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol (2016) (42)
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. (2010) (41)
Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis (2011) (41)
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study. (2012) (40)
Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2008) (40)
Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study. (2011) (40)
The beta-blocker heart attack trial. (1982) (39)
Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"? (2003) (39)
Spatial Distribution of Carotid Intimal‐Medial Thickness as Measured by B‐Mode Ultrasonography (1994) (38)
Clinical trial Data and Safety Monitoring Boards. The search for a constitution. (1995) (38)
Beta-adrenergic blockade for survivors of acute myocardial infarction. (1984) (37)
Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. (1991) (36)
Does Ginkgo biloba Reduce the Risk of Cardiovascular Events? (2010) (36)
Electronic Health Data for Postmarket Surveillance: A Vision Not Realized (2015) (35)
Potential for altering the natural history of congestive heart failure: need for large clinical trials. (1985) (34)
The impact of clinical trials on clinical practice. (1989) (34)
Estrogen Replacement Therapy and MRI‐Demonstrated Cerebral Infarcts, White Matter Changes, and Brain Atrophy in Older Women: The Cardiovascular Health Study (2000) (33)
The unnecessary controversy. (1996) (33)
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. (1989) (33)
Association of Accelerometry‐Measured Physical Activity and Cardiovascular Events in Mobility‐Limited Older Adults: The LIFE (Lifestyle Interventions and Independence for Elders) Study (2017) (32)
Lead editorial: Trials – using the opportunities of electronic publishing to improve the reporting of randomised trials (2006) (32)
Hypertension and outcomes research. From clinical trials to clinical epidemiology. (1995) (32)
Call for worldwide withdrawal of tiotropium Respimat mist inhaler (2012) (32)
Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. (1995) (32)
Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. (2013) (32)
Surrogates, semantics, and sensible public policy. (1997) (31)
Pharmaceutical policies: effects on rational drug use (2006) (30)
Weight Loss, Muscle Strength, and Angiotensin‐Converting Enzyme Inhibitors in Older Adults with Congestive Heart Failure or Hypertension (2005) (30)
Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex (2013) (30)
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. (2012) (30)
Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side. (1995) (30)
Thoughts and Acts of Aggression/Violence Toward Others Reported in Association with Varenicline (2010) (29)
Creatinine levels and cardiovascular events in women with heart disease: do small changes matter? (2004) (29)
Age as a predictor of outcome: what role does it play? (1992) (29)
An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. (2016) (28)
Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance. (2003) (28)
Drug treatment trials in hypertension: a review. (1985) (28)
The Beta-blocker Heart Attack Trial. (1985) (28)
Effect of Cholesterol-Lowering Medications on Progression of Mild Atherosclerotic Lesions of the Carotid Arteries and on the Risk of Stroke (1995) (27)
Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease. (2007) (27)
The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) (1997) (27)
Adverse cardiovascular effects of rofecoxib. (2006) (26)
Risk of psychiatric side effects with varenicline (2009) (26)
When is equal not equal? (2010) (26)
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study (2012) (26)
The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. (1994) (25)
Taking a longer term view of cardiovascular risk: the causal exposure paradigm (2014) (25)
Eligibility for cholesterol referral in community-dwelling older adults. The Cardiovascular Health Study. (1992) (24)
Renin-guided treatment of hypertension: time for action. (2010) (24)
The safety risks of innovation: the FDA's Expedited Drug Development Pathway. (2012) (24)
Effect of long-term prophylactic treatment on survival after myocardial infarction. (1984) (24)
Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: Results from the coronary drug project (2003) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. (1998) (23)
Class effects and evidence‐based medicine (2000) (23)
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 2. Clinical epidemiology: the conceptual basis for interpreting risk factors. (1996) (23)
Calcium antagonists and atherosclerosis. The Multicenter Isradipine/Diuretic Atherosclerosis Study. (1993) (22)
Calcium Antagonists: Antagonists or Protagonists of Mortality in Elderly Hypertensives? (1995) (22)
Social Participation Modifies the Effect of a Structured Physical Activity Program on Major Mobility Disability Among Older Adults: Results From the LIFE Study (2018) (22)
What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. (1983) (21)
Systolic Hypertension in the Elderly Program, Pilot Study (SHEP-PS): morbidity and mortality experience. (1986) (21)
Adrenergic beta-blockade and physical working capacity. (2009) (20)
Lessons Learned from a Prospective Meta‐analysis (1995) (20)
The systolic hypertension in the elderly pilot program: methodological issues. (1988) (20)
JNC VI: timing is everything (1997) (20)
The Randomization Process (2010) (20)
Risk factors, exercise fitness and electrocardiographic response to exercise in 12,866 men at high risk of symptomatic coronary heart disease. (1986) (19)
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2001) (19)
Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study (2010) (19)
Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study (2011) (18)
Current Controlled Trials in Cardiovascular Medicine (2004) (18)
Should every survivor of a heart attack be given a beta-blocker? (1982) (17)
Linked publications from a single trial: a thread of evidence (2014) (17)
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. (2006) (17)
British guidelines on managing hypertension (1999) (17)
Controlling prescription drug expenditures: a report of success. (2007) (17)
Tiotropium and the risk of death in COPD. (2014) (17)
Approaches to data analyses of clinical trials. (2012) (16)
Quality control procedures for the resting electrocardiogram in the Multiple Risk Factor Intervention Trial. (1986) (16)
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) (2017) (16)
Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study (2016) (16)
The use of β-adrenergic blocking drugs in patients with myocardial infarction (1984) (16)
Secondary prevention trials after acute myocardial infarction. (1987) (16)
Tiotropium for chronic obstructive pulmonary disease. (2009) (16)
Introduction to Clinical Trials (2015) (16)
Ischemic episodes in 24-h ambulatory electrocardiograms of elderly persons: the Cardiovascular Health Study. (1995) (16)
Improving cardiac outcomes after noncardiac surgery. (2003) (16)
Is the Use of Some Calcium Antagonists Linked to Cancer? (1998) (15)
Consensus Documents American College of Cardiology Foundation Task Force on Clinical Expert Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the (2008) (15)
Isradipine in Prediabetic Hypertensive Subjects (1998) (15)
The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. (2014) (15)
Procedures of data and safety monitoring committees. (2001) (15)
Improved ECG models for estimation of left ventricular hypertrophy progression and regression incidence by redefinition of the criteria for a significant change in left ventricular hypertrophy status. The MRFIT Research Group. Multiple Risk Factor Intervention Trial. (1993) (14)
The effect of a ganglionic blocking agent (chlorisondamine) on electrocardiogram, physical working capacity and hemodynamics in patients with vasoregulatory asthenia. (2009) (14)
The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Perindopril pROtection aGainst REcurrent Stroke Study. (2002) (14)
Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). (2005) (14)
Corrections to the nifedipine meta-analysis. (1996) (14)
Beta-adrenergic blockade and central circulation during exercise in sitting position in healthy subjects. (1968) (13)
Data monitoring in clinical trials (2006) (13)
Assessment of temporal bias in longitudinal measurements of carotid intimal-medial thickness in the Asymptomatic Carotid Artery Progression Study (ACAPS). ACAPS Research Group. (1996) (13)
THERAPY AND PREVENTION (2005) (13)
Effects of beta-adrenergic blockade on ECG, physical working capacity and central circulation with special reference to autonomic imbalance. (1968) (13)
ACE inhibitors after myocardial infarction. (1993) (13)
Renin test-guided drug treatment of hypertension: the need for clinical trials. (2011) (13)
Secondary Prevention Trials After Myocardial Infarction (1988) (13)
Pluralism of viewpoints as the antidote to intellectual conflict of interest in guidelines. (2012) (13)
Overview of completed sudden death trials: US experience. (1987) (13)
Lipoprotein-Associated Phospholipase A2 and Risk of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study (2009) (13)
Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated (2018) (12)
The causal exposure model of vascular disease (2011) (12)
Clinical implications of the World Health Organization-International Society of Hypertension statement on calcium antagonists. (1997) (12)
To whom do the research findings apply? (2002) (12)
Decisions by regulatory agencies: are they evidence-based? (2007) (12)
The COX-2 inhibitors--an update. (2006) (12)
Lipoprotein‐associated phospholipase A2 and risk of venous thrombosis in older adults (2008) (12)
Psychological risk factors in coronary artery disease. (1987) (12)
Part 1: Rationale and Design (1991) (11)
Sudden coronary death in Scandinavia. A report from Scandinavian coronary heart disease registers. (2009) (11)
Treatment of hypertension: a failing report card. (2009) (11)
Treatment of dyslipidemia: room for improvement? (2000) (11)
Effect of drug therapy on survival in chronic heart failure. (1986) (11)
Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT). (2002) (11)
Sudden cardiac death. Stress and cardiac arrhythmias. (1987) (11)
Pre-Beta1-Lipoprotein: Relationship to Angiographically Proven Coronary Heart Disease and to Lp(a) Lipoprotein (1974) (11)
Public health policies: no place for surrogates. (2012) (11)
Developing an optimal approach to global drug safety. (2001) (11)
National guidelines, clinical trials, and quality of evidence. (2000) (10)
Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk. (2012) (10)
Potential problems with random zero sphygmomanometer (1990) (10)
Contemplating ACTION—long-acting nifedipine in stable angina (2004) (10)
Challenges to the funding of prevention research. (1994) (10)
Experience collecting interim data on mortality: an example from the RALES study (2001) (10)
Antiarrhythmics and VPD suppression. (1991) (10)
Hypertension and diabetes: current issues. (1999) (9)
Inhaled anticholinergics for chronic obstructive pulmonary disease: comment on "Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease". (2011) (9)
Effects of repeated work tests and adrenergic beta-blockade on electrocardiographic ST and T changes. (2009) (9)
The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptions (2001) (9)
Effects of single doses of alprenolol and two cardioselective β-blockers (H 87/07 and H 93/26) on exercise-induced angina pectoris (2004) (9)
Basic Study Design (2015) (9)
Calcium supplements increase risk of myocardial infarction (2010) (9)
Counting events in clinical trials. (1980) (8)
Lessons From the Cardiovascular Health Study Question and Answer Format. (1995) (8)
Adrenergic Beta-receptor Blockade and Anaerobic Metabolism (1966) (8)
The Harms of Antipsychotic Drugs: Evidence from Key Studies (2016) (8)
Assessment of Health-Related Quality of Life (2010) (8)
Should calcium antagonists be first line drugs in hypertension? (1995) (8)
Classification Accuracy of Electrocardiographic Criteria for Left Ventricular Hypertrophy in Normal Weight and Overweight Older Adults (1996) (8)
Potential problems with random zero sphygmomanometer (1990) (7)
Use of angiotensin receptor blockers is associated with decreased risk of dementia in older adults: Secondary analysis of the Ginkgo Evaluation of Memory Study (2012) (7)
Pragmatic trials are randomized and may use a placebo (2010) (7)
Republished: Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications (2014) (7)
Pulmonary function testing in population-based studies. (1997) (7)
Synergistic effects of a new beta-adrenergic blocker (pindolol) and isosorbidedinitrate during exercise in patients with coronary insufficiency (1972) (7)
A new era in hypertension research: discussing the findings of ALLHAT (2001) (7)
Propranolol and angina pectoris. An analysis of the different responses to the drug in patients with angina pectoris. (2009) (7)
Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective (1996) (7)
B-Mode Ultrasound: A Noninvasive Method for Assessing Atherosclerosis (2007) (7)
Calcium channel blocker use and gastrointestinal tract bleeding among older adults. (2002) (7)
Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris. (1975) (7)
Adrenergic beta-receptor blockade and the effect of hyperventilation on the electrocardiogram. (1966) (6)
[The long QT-syndrome]. (1975) (6)
Five years of Trials (2011) (6)
Hormone treatment--misconceptions and agreements. (2002) (6)
SEX-SPECIFIC FAMILIAL CLUSTERING OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROMES (2008) (6)
Lack of age-related differences in the clinical presentation of digoxin toxicity. (1992) (6)
Statistical Methods Used in Interim Monitoring (2015) (6)
Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE‐Inhibitor, or Calcium‐Channel Blocker in ALLHAT (2013) (6)
GOLD COPD stage I is not associated with increased risk of death. (2012) (6)
AHA Conference Report on Cholesterol. Intervention studies. (1989) (6)
Lipid-lowering trials: results and limitations. (1994) (6)
Organizing multicenter trials: lessons from cardiovascular prevention trials. (1991) (6)
Data Collection and Quality Control (2015) (6)
Report of the independent panel considering the retraction of two articles in The BMJ (2014) (6)
The use of beta-adrenergic blocking drugs in patients with myocardial infarction. (1984) (5)
Monitoring Response Variables (2010) (5)
Comparison of the design differences between the Ginkgo Evaluation of Memory study and the Guidage study (2008) (5)
What are the weaknesses of randomized controlled clinical trials (2007) (5)
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes (2008) (5)
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? (2013) (5)
Prospective pravastatin pooling project: Relative risk reduction by baseline HDL and TG concentrations (2000) (5)
Issues in Data Analysis (2010) (5)
Blood-pressure-lowering treatment (2001) (5)
Adrenergic Beta-receptor Blockade and the Relationships between Physical Working Capacity, Heart Volume, and the Total Amount of Hemoglobin (1967) (5)
Time trends in the use of anti‐hypertensive medications: results from the Multi‐Ethnic Study of Atherosclerosis (2009) (5)
Carotid Doppler high-intensity transient signals in dilated cardiomyopathy. (2000) (5)
Effects of calcium channel blockers on survival after myocardial infarction (1987) (5)
Long-term Risk of Cardiovascular Events With Rosiglitazone (2016) (5)
Outpatient management of severe COPD. (2010) (5)
Beta-adrenergic blockers in the prevention of sudden death. (1985) (4)
PAPER I: Electrophoresis of Lipoproteins on Cellulose Acetate Membrane (2009) (4)
Lipid lowering therapy in CAD patients at Academic Medical Centers: undertreatment and evidence of a gender gap (1998) (4)
Review: hormone replacement therapy may reduce the risk for death in younger but not older postmenopausal women. (2005) (4)
Doxazosin, an inferior antihypertensive agent? (2002) (4)
The National Heart, Lung, and Blood Institute Workshop on Antihypertensive Drug Treatment: The Benefits, Costs, and Choices (1989) (4)
Systolic hypertension in the elderly program (SHEP). I, Rationale and design (1991) (4)
Unsuccessfully Treated Hypertension: A Major Public Health Problem With a Potential Solution. (2017) (4)
Use of beta-adrenergic blocking agents after myocardial infarction. (1985) (4)
β-Blocker Heart Attack Trial (1983) (4)
[Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program]. (1996) (4)
Comparisons in a competitive world: when is one drug superior to another? (2000) (4)
Plasma Renin Testing to Guide Antihypertensive Therapy (2014) (4)
Quarter Watch: 2008 Quarter 1 : QUARTER WATCH PROJECT TEAM * (2009) (4)
Dosing of atorvastatin and increases in fibrinogen level. (1999) (4)
Comparison of Effects on Left Ventricular Filling Pressure of Intravenous Nesiritide and High-Dose Nitroglycerin in Patients With Decompensated Heart Failure (2004) (4)
Understanding drug safety and how to maximize it for patients. (2011) (4)
Are there fundamental deficiencies in the megatrial methodology? (2001) (4)
Assessment and Reporting of Harm (2015) (4)
Use of Diuretics in Treatment of Hypertension in the Elderly (2012) (4)
Assessing and Reporting Adverse Events (2010) (4)
Balancing commercial and public interests (2004) (4)
PAPER III: Familial Occurrence of an Extra Pre‐beta Lipoprotein Fraction (2009) (3)
What is the Question (1996) (3)
Nimodipine and the "no-reflow phenomenon"--experimental triumph, clinical failure? (1989) (3)
A pilot test of a new tool for remote blood pressure monitoring (2014) (3)
Effect of aptin, a beta-adrenergic blocking agent, in arterial hypertension. (1969) (3)
Age as a modifi able risk factor for cardiovascular disease (2008) (3)
NIFEDIPINE TRIALS. AUTHORS' REPLY (1996) (3)
SERUM PRE-β-1 LIPOPROTEIN FRACTION IN CORONARY ATHEROSCLEROSIS (2009) (3)
Are all drugs of a class interchangeable (2007) (3)
O3-04-02: The Ginkgo in evaluation of memory (GEM) study: Primary outcomes in a longitudinal dementia prevention trial (2008) (3)
Achilles reflex time and sympathetic tone. (1973) (3)
How should one analyse and interpret clinical trials in which patients don't take the treatments assigned to them? (2010) (3)
Behavioral consequences of hypertension and antihypertensive therapy. (1987) (3)
ALLHAT and calcium channel blockers. ALLHAT Research Group. (1997) (3)
FAMILIAL QT PROLONGATION and RISK OF SUDDEN DEATH (1975) (3)
Response to Letter Regarding Article, “Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)” (2006) (3)
Lessons From Warfarin Trials in Atrial Fibrillation: Missing the Window of Opportunity (2006) (3)
Systolic hypertension in the elderly: controlled or uncontrolled. (1990) (3)
Is the Guideline Process Replicable and, if Not, What Does This Mean? (2015) (3)
Turning over a new leaf (2008) (3)
Can we measure and predict atherosclerotic progression? (1993) (3)
Hormone therapy: time for replacement? (1999) (2)
JNC VI guidelines (1998) (2)
Penicillin and working capacity. (1967) (2)
Isolated Systolic Hypertension and Subclinical Cardiovascular Disease in the Elderly: Initial Findings from the Cardiovascular Health Study (1993) (2)
Calcium Antagonists and Cancer: Causation or Association? (1998) (2)
PAPER V: Myocardial Infarction and an Extra Pre‐beta Lipoprotein Fraction (2009) (2)
Expedited review of new drugs--reply. (2013) (2)
Effects of hyperventilation on ECG in patients with circulatory disturbances. (2009) (2)
Community hospitals in clinical trials. (1982) (2)
Recruitment of Study Participants (2015) (2)
Commentary Withdrawal of cerivastatin from the world market (2001) (2)
Cardiovascular disease risk prediction factors. (2012) (2)
PAPER II: Angina of Effort and an Extra Pre-beta Lipoprotein Fraction (2009) (2)
Dyslipoproteinemia in North America: The Lipid Research Clinics Program Prevalence Study. (1986) (2)
Hypertensive cardiovascular disease and the treatment of hypertension in the elderly. (1994) (2)
A randomized study of 5-fluorouracil and filtration surgery. (1988) (2)
Effect of beta-blocker therapy on recurrent nonfatal myocardial infarction. (1983) (2)
Preventive cardiology academic award (1986) (2)
Predictors of carotid atherosclerosis progression (1994) (2)
Relative impact of lovastatin and estrogen replacement therapy on progression of intimal-medial thickness in the carotid arteries (1994) (2)
Evidence-based medicine: worship of form and treatment of high blood pressure. (2000) (2)
Adrenergic beta-receptor blockade and ECG changes of organic origin. (1967) (2)
Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure (2004) (2)
EFFECT OF APTIN, A β‐ADRENERGIC BLOCKING AGENT, IN ARTERIAL HYPERTENSION (2009) (2)
Task Force 4: Behavioral consequences of hypertension and antihypertensive therapy (1987) (2)
Primary Prevention of Cardiovascular Disease Endpoints Using β-Blockers-Reply (1997) (2)
Reporting and Interpreting of Results (2010) (2)
PLACEBO CONTROLLED DOUBLE BLIND TRIALS (1980) (1)
[Stopping smoking prolongs life]. (1975) (1)
O1-01-08 The Ginkgo in evaluation of memory (GEM) study design, recruitment, and incident dementia rates: A preliminary report (2007) (1)
What happened to the study subjects who disappeared from the analysis (2007) (1)
What are the strengths of observational studies (2007) (1)
β-Adrenergic Receptor Blocking Drugs in Hypertrophic Cardiomyopathy, Autonomically Mediated Cardiovascular Functional Disorders and Fallot’s Tetralogy (2012) (1)
Effect of Beta-blocker Therapy (2005) (1)
Beta-adrenergic blockers in patients with acute myocardial infarction. (1989) (1)
Current Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com) (2000) (1)
How are adverse drug reactions measured (2007) (1)
Can the results of HOPE be extrapolated to all ACE inhibitors (2000) (1)
Thursday, 5/18, Trianon Ballroom, 5:00 pm–6:00 pm Theme II: Should Dihydropyridines Be Used for First Line Treatment?SHOULD DIHYDROPYRIDINES BE USED FOR FIRST LINE TREATMENT? THE “CON” SIDE (1995) (1)
Adverse events in clinical trials: is a new approach needed? (2008) (1)
Clinical trials of platelet-active drugs in coronary heart disease: summary of design features. (1980) (1)
Are drugs interchangeable? (2000) (1)
[Preventive cardiology in Norrbotten]. (1972) (1)
Risk of psychiatric side effects with varenicline. Authors' reply (2009) (1)
JNC 8: shortcomings in process and treatment recommendations. (2014) (1)
Relation of exercise electrocardiographic st changes to physiological measurements in men at high risk of future coronary death (1981) (1)
Observed Benefits of Antihypertensive Drug Treatment Results of the Trials of Traditional Therapy Controlled Clinical Trials of Drug Treatment for Hypertension (2005) (1)
Adrenergic beta-receptor blockade in neurocirculatory asthenia (1969) (1)
Why is blinding/masking so important? (2007) (1)
What are the weaknesses of observational studies (2007) (1)
PAPER IV: Variations in Pre‐beta Lipoproteins after a Test Meal (2009) (1)
臨床試験とは何か : What clinicians need to know about clinical trials (1998) (1)
Calcium channel blocker use and gastrointestinal tract bleeding among older adults (2001) (1)
Surgical bleeding and calcium antagonists: Authors’ reply (1995) (1)
EFFECT OF PRAVASTATIN IN PEOPLE WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS: PD.8 (2005) (1)
[Calcium antagonists: safe or unsafe?]. (1996) (1)
Monitoring Committee Structure and Function (2015) (1)
Medications and cardiovascular health in older adults: room for improvement in prevention and treatment. (2004) (1)
Clinical Trials of Modification of Mortality During Acute Myocardial Infarction (1985) (1)
Why is benefit-to-harm balance essential to treatment decisions? (2007) (1)
Antidepressants , allergy drugs among 87 products with signals for insomnia Liver failure and antiviral failure with hepatitis C direct-acting drugs Harms of antipsychotic drugs reappraised Executive Summary (2017) (0)
Monitoring Committees: Why and How (2006) (0)
[A clear winner and two losers]. (2009) (0)
mellitus undergoing coronary artery bypass grafting improve neurologic or neurobehavioral outcomes in patients without diabetes Attempted control of hyperglycemia during cardiopulmonary bypass fails to (2013) (0)
Implications for Research (1989) (0)
The author9s reply (2009) (0)
Is it necessary to be a biostatistician to interpret scientific data (2007) (0)
Stopping a Trial for Futility: The Cooperative New Scandinavian Enalapril Survival Study II (2006) (0)
Thanks to all those who reviewed for Trials in 2014 (2015) (0)
Consensus Reports (2011) (0)
Counterpoint: statins do reduce fatal events. (2013) (0)
CALCIUM CHANNEL BLOCKERS AND CARDIOVASCULAR RISK IN DIABETES. AUTHORS' REPLY (1998) (0)
Book Reviews (2007) (0)
Thursday, May 14, Broadway Ballroom North, 10:30 AM: Theme III: Drug Safety (1998) (0)
inappropriate methods Digitalis--a new controversy regarding an old drug. The pitfalls of (2011) (0)
' s response to reviews Title : Clinical efficacy and prognostic indicators for lower limb pedalling exercise early after stroke : A pilot randomised controlled trial (2011) (0)
Authors' reply (1995) (0)
Clinical Trials in Hypertension and Congestive Heart Failure (1986) (0)
Introduction to Case Studies Showing Harmful Effects of the Intervention (2006) (0)
Mortalityassociatedwithtiotropiummistinhalerinpatients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials (2011) (0)
The Systolic Hypertension in the Elderly Program (SHEP): Rationale, Design, Recruitment, and Baseline Data (1989) (0)
E5 Cost-effectiveness of first-line drugs for uncomplicated hypertension (1997) (0)
Response to Letter Regarding Article, “Physical Activity and Incidence of Atrial Fibrillation in Older Adults: The Cardiovascular Health Study” (2009) (0)
Principles of clinical trials: US viewpoint. (1980) (0)
ANTIHYPERTENSIVE MEDICATIONS. AUTHORS' REPLY (1998) (0)
Women as participants in cardiovascular trials (1986) (0)
[Alfadil--positive documentation when it comes to safety is missing]. (2003) (0)
Pravastatin reduces mortality: The Prospective Pravastatin Pooling Project (2000) (0)
Calcium channel blockers and cardiovascular risk in diabetes (1998) (0)
Does publication in a reputable scientific journal guarantee quality (2007) (0)
Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Gastrointestinal Drugs Advisory Committee (2001) (0)
School and home interventions improved children's dietary and physical activity behaviors. (1997) (0)
Characteristics and Baseline Clinical Predictors of Future Fatal Versus Nonfatal Coronary Heart Disease Events in Older Adults The Cardiovascular Coronary Heart Disease (2006) (0)
More on calcium channel blockers in nephrology. (1997) (0)
Author Response. (2014) (0)
P109 The role of a Regional Resource Center in a large multicenter clinical study (1995) (0)
Review: hormone therapy may reduce the risk of death in younger but not older postmenopausal women (2005) (0)
Survival analysis of adverse effects data in the BHAT (1985) (0)
Protocol deviations due to side effects in the SHEP pilot study (1986) (0)
The Role of Beta-Blockers in Cardioprotection (1981) (0)
How well is research translated into clinical care (2007) (0)
Introduction to Case Studies With Special Issues (2006) (0)
Were the scientific questions stated in advance (2007) (0)
Do meta-analyses provide the ultimate truth? (2007) (0)
Hormone treatment: misconceptions and agreements. Authors' reply (2002) (0)
["Lipid research clinics"--a new concept in clinical atherosclerosis research]. (1975) (0)
Meta-analysis of Hypertension Trials in Diabetic Patients Response to Parving and Rossing (2001) (0)
Should a Change in the Atherosclerotic Process be Required for Approval of New Hypolipidemic Agents (1989) (0)
THE HYPERTENSION PARADIGM (2019) (0)
Pilot Study of the Systolic Hypertension in the Elderly Program Type of event ICD number Outline of criteria for event Hypertensive Stroke Left ventricular failure Transient ischemic attack Atherosclerotic Myocardial infarction Sudden death Angina pectoris Coronary artery surgery (2005) (0)
Workshop V Intervention Studies (2005) (0)
How is symptomatic improvement measured (2007) (0)
THE MULTICENTER ISRADIPINE DIURETIC ATHEROSCLEROSIS STUDY (MIDAS). AUTHORS' REPLY (1997) (0)
The secondary prevention trials. Lessons learned, questions raised. (1988) (0)
How reliable are active-control trials? (2007) (0)
Methodological considerations of withdrawal studies (1984) (0)
Reversing risk in coronary disease (1995) (0)
What is the purpose of this book (2007) (0)
Independent and additive associations of non-steroidal anti-inflammatory drugs (NSAID's) and aspirin with increased prevalence of hypertension in the elderly (1998) (0)
[Hypertension in the aged]. (1981) (0)
Questioning statin therapy for older patients (2020) (0)
[EFFECT OF PENICILLIN ON THE PHYSICAL CAPACITY FOR WORK AND ON THE EXPERIENCE OF FATIGUE DURING WORK]. (1963) (0)
Comparison of calcium channel blockers with other classes of drugs for hypertension (2006) (0)
Lipoproteins and cardiovascular risk. Authors' reply (2003) (0)
Predictors of carotid atherosclerosis progression among women (1995) (0)
Editorial Are there fundamental deficiencies in the megatrial (2001) (0)
Should dihydropyridines be used for first line treatment (1995) (0)
Calcium channel blockers in myocardial infarction: Authors' reply (1990) (0)
P4-353: The Ginkgo Evaluation of Memory (GEM) Study: Lessons on adherence and retention in dementia primary prevention trials (2008) (0)
Task Force 1: Sudden cardiac death (2005) (0)
Preventive health program in Norrbotten with special reference to heart diseases. (1972) (0)
Insitute for Safe Medication Practices Quarter Watch : 2008 Quarter 1 October 23 , 2008 Executive Summary (0)
What CHF Trials have Shown to Date and What is Needed (1987) (0)
The Costs of Antihypertensive Therapy-Reply (1996) (0)
assigned to them ? How should one analyse and interpret clinical trials in which patients don ' t take the treatments (2010) (0)
Lessons from the BHAT Study Regarding Selection of Patients Post Myocardial Infarction for Beta Blockade (1985) (0)
Is it really possible to assess quality of life (2007) (0)
Chlorthalidone vs Other Low-Dose Diuretics—Reply (2004) (0)
Low-dose metoprolol CR/XL and fluvastatin slowed progression of carotid atherosclerosis in asymptomatic patients with carotid plaque: Ramipril had a beneficial effect on the progression of atherosclerosis in patients at high risk for cardiovascular events (2001) (0)
Current treatments of cardiovascular diseases are unlikely to produce more than moderate reductions in mortality (1985) (0)
Antihypertensive medications [2] (multiple letters) (1998) (0)
[Reduce prescription of expensive drugs without increased value]. (2003) (0)
How representative are study subjects in clinical trials (2007) (0)
The pitfalls of inappropriate methods (2005) (0)
What are the strengths of randomized controlled clinical trials (2007) (0)
[The effect of a ganglionic-blocking substance on the orthostatic reaction and physical working capacity in lying and sitting positions in normal subjects]. (1966) (0)
P17 Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study (1993) (0)
Mega-trials: the Prospective Pravastatin Pooling Project (PPP) and the Heart Protection Study (HPS) (2003) (0)
Task Force 2 : Psychological risk factors in coronary artery disease (2005) (0)
Effect of lovastatin on early carotid atherosclerosis in women (1994) (0)
Hospitalization For Pneumonia Is Associated With Increased Risk Of Dementia In Older Adults (2012) (0)
Panel discussion. I: Cost effectiveness of drug development and health economics. (1989) (0)
Muscle pains and/or CK-elevation during HMG-CoA-reductase inhibitor therapy are frequently associated with increased isoprostane (2000) (0)
What Are the Postulated Mechanisms Behind Stroke Reduction With Statins ? (1998) (0)
Evaluating professional performance in cardiovascular medicine. (2006) (0)
[Value of exercise tests in coronary disease. (5). Beta-receptor adrenergic block in ECG diagnosis in connection with exercise tests]. (1966) (0)
Title : Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting : a meta-analysis of 7 double-blind , placebo-controlled , randomized clinical trials (2012) (0)
Study on pre-beta1 lipoprotein fraction. (1973) (0)
[ACCOMPLISH and the risks with company sponsored clinical trials]. (2009) (0)
Beta-adrenergic receptor blocking drugs in hypertrophic cardiomyopathy, autonomically mediated cardiovascular functional disorders and Fallot's tetralogy. (1974) (0)
Do changes in biologic markers predict clinical benefit (2007) (0)
Nolan J, Ghuran A, Uren N. Emergency Cardiology: An Evidenced-Based Guide to Acute Cardiac Problems. Oxford: Hodder and Stoughton, 2003. (ISBN 0340807199, 256 pp. paperback. US$26.50; £17.99). (2005) (0)
Author's response to reviews Title: Dealing with Heterogeneity of Treatment Effects: Is the Literature Up to the Challenge? A Systematic Review Authors: (2009) (0)
How informative are composite outcomes (2007) (0)
Angiotensin-converting enzyme inhibitors and diuretics: Optimal combination therapy [8] (multiple letters) (2004) (0)
' s response to reviews Title : The effectiveness of VIPP-V parenting training for parents of young children with a visual or visual-and-intellectual disability : Study protocol of a multicenter randomized controlled trial (2015) (0)
Women's health and diet (1994) (0)
What do New Cardiovascular Agents (e.g. Antiarrhythmic Drugs) Have to Show to Establish a Favorable Risk versus Benefit Ratio to Obtain Approvability? — Clinical Viewpoint (1989) (0)
Should experts with potential conflicts of interest be allowed to serve on FDA advisory panels (2005) (0)
Antihypertensive drugs decrease risk of Alzheimer disease Ginkgo Evaluation of Memory Study (0)
Tiotropium in chronic obstructive pulmonary disease. (2009) (0)
PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE ENDPOINTS USING BETA -BLOCKERS. AUTHORS' REPLY (1997) (0)
In reply [8] (2006) (0)
General cardiology TO WHOM DO THE RESEARCH FINDINGS APPLY ? (2002) (0)
Drug safety: the different perspectives. (1998) (0)
Secondary Trials After Myocardial Infarction: A Review (1983) (0)
Thanks to all those who reviewed for in 2014. (2015) (0)
Conference Report From the American Diabetes Association and the Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus (2008) (0)
Treatment to Prevent Heart Attack Trial : Results by Sex Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering (2013) (0)
[RESEARCH ON THE EFFECT OF PAPAVERINE ON THE OBSTRUCTED URETER]. (1964) (0)
Introduction to Case Studies Showing Benefit from the Intervention (2006) (0)
Thanks to all those who reviewed for Trials in 2015 (2016) (0)
Saturday May 31, Ballroom A, 9:00 am Theme III: The “Rules” of Evidence in Clinical Medicine: Calcium Antagonists—A Case in Point: The “rules” of evidence in clinical medicine: Calcium antagonists — A case in point. Clinical trials (1997) (0)
The association between LDL-C and outcome: The pravastatin pooling project (2000) (0)
How trustworthy are the authors (2007) (0)
Were the treatment groups comparable initially (2007) (0)
Committee Reports & Consensus Statements (2006) (0)
Behavioral Sciences in Clinical Trials: An Overview (1982) (0)
Chlorthalidone vs other low-dose diuretics. Authors' reply (2004) (0)
How should I handle the massive flow of information (2007) (0)
Introduction. Tribute to John Laragh, MD - clinician and scientific researcher. (2014) (0)
Long term oestrogen plus progestin increased venous thromboembolism and biliary tract surgery in postmenopausal women (2003) (0)
10 – The Role of Beta Blockers in the Prevention of Sudden Cardiac Death in the Postinfarction Patient (1986) (0)
tice of medicine and to ensure the health of the public. We continue to believe that treatment trials should use low-dose diuretics as the standard for clinically useful comparisons. (2017) (0)
In reply (1998) (0)
Hormone treatment - Misconceptions and agreements [4] (multiple letters) (2002) (0)
802-6 The Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Heart Disease (1995) (0)
Evidence-based medicine (2000) (0)
The evolution of public health sciences in an academic medical center. (2002) (0)
Triumph, Clinical Failure? (2006) (0)
Clinical trials. (1982) (0)
' s response to reviews Title : Effects of Anma-massage therapy ( Japanese massage ) for gynecological cancer survivors : study protocol for a randomized controlled trial (2013) (0)
Clinical trials in hypertension. Authors' reply (2006) (0)
Coronary heart disease in the elderly : Working Conference on the Recognition and Management of Coronary Heart Disease in the Elderly, held September 4-6, 1985, at the National Institutes of Health, in Bethesda, Maryland, U.S.A. (1986) (0)
What is the value of biologic markers in drug evaluation (2007) (0)
IEWPOINT rom Knowledge to Practice in Chronic ardiovascular Disease : A Long and Winding Road (2016) (0)
How much confidence can be placed on economic analysis (2007) (0)
Stopping the Randomized Aldactone Evaluation Study Early for Efficacy (2006) (0)
Preventing atherosclerosis and its complications: Promising alternatives for the future: Introduction (1994) (0)
Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS (1994) (0)
Who Should Fund Clinical Trials (1982) (0)
Developing an optimal approach to global drug safety (2001) (0)
TOWARD IDENTIFYING PERSONALIZED PROGNOSIS IN HYPERTENSION: VARIATION IN EARLY RESPONSES IN THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) (2017) (0)
Microsoft Word - CRD378BF (2008) (0)
Can Atherosclerotic Progression and Its Complications Be Prevented After Revascularization ? Overview of the Pathogenesis of Bypass Graft Closure and Post-PTCA Restenosis Saphenous Vein Bypass Graft Disease (2005) (0)
Clinical Trials in Hypertension—Reply (2006) (0)
Abstract 11409: Lipoprotein-Associated Phospholipase A2 is Associated with Incident Peripheral Arterial Disease: The Cardiovascular Health Study (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Curt D. Furberg?

Curt D. Furberg is affiliated with the following schools: